Literature DB >> 15006719

COX inhibitors and their effects on bone healing.

Louis C Gerstenfeld1, Thomas A Einhorn.   

Abstract

Prostaglandins (PGs) are released as part of the inflammatory response. They are synthesised from arachidonic acid by the cyclooxygenase enzymes, COX-1 and -2. NSAIDS inhibit COX activity and have become the primary means of alleviating chronic pain associated with rheumatoid and osteoarthritis. They are also widely used as analgesics in the treatment of acute postsurgical and traumatic pain. PGs are known to play important functions in bone repair and normal bone homeostasis. Animal studies suggest that, whilst both nonspecific and specific inhibitors of COXs impair fracture healing, some studies have suggested that this impairment is due to COX-2. Although these data raise concerns about the use of COX-2-specific inhibitors as anti-inflammatory or analgesic drugs in patients undergoing orthopaedic procedures, clinical reports have been largely inconclusive concerning the effects of NSAIDs on bone healing. Since animal data suggest that the effects of COX-2 inhibitors are both dose-dependent and reversible, in the absence of scientifically sound clinical evidence it is suggested that physicians consider short-term administration or use of other drugs in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006719     DOI: 10.1517/eods.3.2.131.27335

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  18 in total

1.  Fragility Fractures Are Associated with an Increased Risk for Cardiovascular Events in Women and Men with Rheumatoid Arthritis: A Population-based Study.

Authors:  Orla Ni Mhuircheartaigh; Cynthia S Crowson; Sherine E Gabriel; Veronique L Roger; L Joseph Melton; Shreyasee Amin
Journal:  J Rheumatol       Date:  2017-01-15       Impact factor: 4.666

Review 2.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

3.  Comment on Peerbooms et al.: No positive bone healing after using platelet rich plasma in a skeletal defect. An observational prospective cohort study.

Authors:  Andrew Quaile
Journal:  Int Orthop       Date:  2012-07-20       Impact factor: 3.075

4.  Influence of Pain and Analgesia on Orthopedic and Wound-healing Models in Rats and Mice.

Authors:  Monika K Huss; Stephen A Felt; Cholawat Pacharinsak
Journal:  Comp Med       Date:  2019-09-27       Impact factor: 0.982

5.  Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries?

Authors:  Stuart J Warden
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

6.  An Ovine Model of In Vivo Bioreactor-Based Bone Generation.

Authors:  Emma Watson; Alexander M Tatara; Jeroen J J P van den Beucken; John A Jansen; Mark E Wong; Antonios G Mikos
Journal:  Tissue Eng Part C Methods       Date:  2020-07-07       Impact factor: 3.056

7.  Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult.

Authors:  Fergus E McKiernan
Journal:  Osteoporos Int       Date:  2005-05-19       Impact factor: 4.507

Review 8.  Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative.

Authors:  Cory J Xian; Xin-Fu Zhou
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02

9.  Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture.

Authors:  Panagiotis Akritopoulos; Paraskevi Papaioannidou; Ippokratis Hatzokos; Afroditi Haritanti; Eirini Iosifidou; Maria Kotoula; Vassiliki Mirtsou-Fidani
Journal:  Arch Orthop Trauma Surg       Date:  2008-08-02       Impact factor: 3.067

10.  Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression.

Authors:  Damian C Genetos; Clare E Yellowley; Gabriela G Loots
Journal:  PLoS One       Date:  2011-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.